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Development of an Assessment Tool for Good Distribution
Practice for a Regulatory Agency in West Africa
U.G. Okafor 1, Z. Ekeocha 2, S. Byrn 3, K. Clase 4, Shiihii Solomon Ukavenda5

ABSTRACT
Good Distribution Practice (GDP) refers to the regulatory guidelines governing the wholesale and distribution of
medicinal products to ensure that their quality and integrity are maintained throughout the supply chain from the
manufacturer to the end users. A standard assessment tool for GDP is necessary in order to conduct a robust
assessment on GDP on pharmaceutical industries. The observed agency’s policy and operational documents in
addition to GDP Guidelines from World Health Organization and related organizations from various countries
were reviewed. The observed Regulatory Agency does not have a separate assessment tool for GDP
inspection. Few core GDP parameters are captured in a section of the GMP reporting format. The included
parameters addressed the activities in the production areas and do not address the major distribution activities
and processes. Thus, it is unlikely that a robust inspection will be carried out in the absence of a separate GDP
assessment tool. There is need for a separate and robust GDP assessment tool, training of inspectors in line
with the tool and a separate GDP inspection, outside the GMP inspection, Majority of the GDP guidelines
reviewed from various countries were in line with the World Health Organization’s GDP guideline. Based on the
findings, an Assessment Tool for Good Distribution Practice was developed for the agency, to be applied to all
distributors, coordinated wholesale centres, wholesalers and retailers. There is need for the agency to adopt the
Assessment Tool, develop its own guidelines for GDP and train all pharmaceutical inspectors on uniform
assessment and interpretation of indices, reporting of observations and conclusions.
Keywords: good distribution practice (GDP), inspection, assessment tool, training, regulatory agency

INTRODUCTION
Distribution is an important activity in the integrated
supply-chain management. It involves the movement
of pharmaceutical products from the premises of the
manufacturer of such products, or another central
point, to the end user, or to an intermediate point by
means of various transport methods, via various
storage and/or health establishments (Middha et al.,
2018).Good Distribution Practice (GDP) refers to the
regulatory guidelines governing the wholesale and
distribution of medicinal products to ensure that their
quality and integrity are maintained throughout the
supply chain from the manufacturer to the end users
(Pharma Experts, 2019). Good Distribution
Practices (GDP) is a quality system for warehouse
and distribution centers dedicated for medicines.
Maintaining product safety and quality during

distribution is of utmost importance in the
pharmaceutical industry (WHO, 2010).
Internationally accepted pharmaceutical GDP
regulations stipulate that distributors of
pharmaceutical products must align their operations
with the standards. These regulations ensure that
consistent quality management systems are in place
throughout the entire supply chain, from the early
delivery of raw materials to the manufacturing plants,
to the final shipment of finished drugs to the end
user. GDP extends beyond the distribution of the
finished products and includes the sourcing, storage
and transportation of Active Pharmaceutical
Ingredients and other ingredients prior to
manufacturing (WHO, 2005).
Good Distribution Practice (GDP) ensures the quality
and identity of pharmaceutical products during all
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aspects of the distribution process and avoids the
introduction of counterfeits into the marketplace via
the distribution chain. These aspects include, but
are not limited to, procurement, purchasing, storage,
warehousing, handling, holding, displaying,
marketing, distribution, transportation, repackaging,
relabeling, documentation and record-keeping
practices, in the public and private sectors for
finished pharmaceutical products (WHO, 2010).
Counterfeit pharmaceutical products are a real threat
to public health and patient safety. Consequently, it
is essential to protect the pharmaceutical supply
chain against the penetration of such products.
Weak points in the distribution processes of
pharmaceutical products provide an avenue for
counterfeit as well as illegally imported, stolen and
substandard medicines to enter the supply chain.
This is a concern in both developed and developing
countries. The methods by which such products
enter the supply chain have become increasingly
complex and have resulted in the development of
thriving secondary and grey markets throughout the
world. The involvement of unauthorized entities in
the distribution and sale of pharmaceutical products
is a particular concern. Only a joint approach
including all parties involved in the supply chain can
be successful in the fight against counterfeit
pharmaceutical products and, therefore, all parties
active in the market should take an active part in
collaborative activities. Different models for the
distribution of pharmaceutical products are used in
different countries and sometimes within the same
country, for example, in the public and the private
sectors (WHO, 2010).
To maintain the original quality of pharmaceutical
products, every party active in the distribution chain
has to comply with the applicable legislation and
regulations. However, though few core GDP
parameters are captured in the Good Manufacturing
Practice (GMP) Reporting Format which also serves
as the GMP Assessment Tool of the Observed
Regulatory Agency in West Africa, the agency does
not have a separate Assessment Tool for Good
Distribution Practice inspections. Therefore, the aim
of this study is twofold. The first aim is to review the
Observed Agency’s GMP Assessment Tools for
inspection in addition to WHO guidelines on GDP
and those of related agencies in other countries. The
second aim is to utilize the review in developing a
GDP Assessment Tool for the Observed Regulatory
Agency in West Africa. This new GDP Assessment
Tool would be developed in line with applicable
legislation and regulations, specifically for the
inspection of any premises involved in all forms of
distribution of pharmaceutical products, from the

premises of the manufacturer of the products to the
person dispensing or providing pharmaceutical
products directly to a patient or his or her agent. The
GDP Assessment Tool shall apply to all premises
involved in any aspect of the distribution of
pharmaceutical products from the manufacturing site
to the point of use, including government at all
levels, public and private health institutions and
storage facilities, manufacturers of finished
pharmaceutical products, importers, exporters,
distributors, wholesalers, suppliers, retailers,
freighters, logistics providers, transport companies
and forwarding agents and their employees (WHO,
2010).

METHODS
This study was conducted from October 2019 to
February 2020. A qualitative method consisting of
review of policy and operational documents was
used to achieve this objective (Fig.1). The major
documents reviewed were (a) World Health
Organization (WHO) Good Distribution Practices for
Pharmaceutical Products, (b) WHO Guide to Good
Storage Practices for Pharmaceuticals, (c) WHO
Guide for Inspection of Drug Distribution Channels,
(d) GDP Guidelines of the National Agency for Food
and Drug Administration and Control, Nigeria, (e)
Pharmaceutical Inspection Convention/
Pharmaceutical Inspection Co-operation Scheme
(PIC/S), (f) European Compliance Academy
Pharmaceutical Product Quality Group (ECA-PQG),
(g) Guidance on the Interpretation and
Implementation of EU GDP, and (h) National Drug
Authority Uganda GDP Guidelines and Audit
Agenda, Checklist, Report and Standard Operating
Procedures being used by a WHO Prequalified
Manufacturing Industry in Africa. In addition, a Gap
Analysis was carried out by reviewing the GMP
Reports from various regional offices of the
Observed Regulatory Agency in West Africa for
consistency in assessment, interpretation and
reporting of specific indices and observations with
respect to the GDP component. Other documents of
the Observed Regulatory Agency in West Africa
reviewed included (a) Inspection Format and (b)
Scoring Format for Inspection of Pharmaceutical
Distribution and Manufacturing Outlets, used for
accreditation as internship training centres. By
summarizing, analyzing, and synthesizing this group
of related literature, it was feasible to develop a new
tool and also evaluate the quality of existing tools
against a criterion to reveal weaknesses,
inconsistencies, and contradictions (Paré et al.,
2015). Ethical approval was not required for this
study since no personal sensitive data were found in
any documents reviewed.
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RESULTS
It was observed that though some few core GDP
parameters were captured in a section of the GMP
reporting format, the Observed Regulatory Agency in
West Africa, does not have a separate Assessment
Tool for new and routine GDP inspections.

Figure 1
Flow Chart of Document Review
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The parameters captured in the GMP reporting
format which also serves as the assessment tool for
GMP inspections were name, address, contact, key
personnel and their current practicing licenses, if
applicable, current certificate of registration of the
premises, list of products, transportation and
handling of starting materials, packaging materials
and finished products, distributor’s accreditation
guidelines, standard operating procedures for
product recall and list of distributors. In addition,
there was a disconnect among pharmaceutical
inspectors in various regions of the country in the
way by which assessment, interpretation and
reporting of indices, observations and conclusions of
the GDP parameters were made; these parameters
are subjectively assessed, interpreted and reported
by various inspectors in the Agency (Table 1).

Table 1
Relevant Information on GDP in the Current GMP Assessment Tool of the Observed Regulatory Agency in West Africa (Percentages
indicate frequency of reporting)

Indicators

Values

Percentages

Name

0

0%

Address

0

0%

Contact (Telephone)

3

9%

Contact (Email)

5

14%

Key personnel

2

6%

Current practicing license (Superintendent Pharmacist)

12

34%

Current practicing license (Pharmacist's Director)

12

34%

Current practicing license (Other Pharmacists)

8

23%

Current certificate of registration of premises

11

31%

4

List of products

0

0%

Transportation and handling of starting materials

3

9%

Packaging materials (Types)

6

17%

Packaging materials (Records)

15

43%

Finished Products (Quarantine)

6

17%

Finished Products (Approved product store)

8

23%

Distributors accredited guidelines

10

29%

SOPs of product recall

15

43%

List of distributors

15

43%

5

From Table 2, majority of the GDP guidelines
reviewed from various countries were in line with
the WHO GDP guideline apart from few differences
in the indicators such as specific provisions for
brokers, donated pharmaceutical products,

measurement analysis and improvement. The
particular indicators required or not required as
standard practice in the guidelines and assessment
tools of the various countries are indicated (Table
2).

Table 2
Data Extracted from the Various GDP Guidelines and Assessment Tools

INDICATORS

WHO

NIGERIA

UGANDA

PIC/S

ECA-PQG

Introduction

Required

Required

Required

Required

Required

Organization and management

Required

Required

Required

Required

Required

Personnel

Required

Required

Required

Required

Required

Quality system

Required

Required

Required

Required

Required

Premises, warehousing and storage

Required

Required

Required

Required

Required

Vehicles and equipment

Required

Not
Required

Required

Required

Required

Shipment containers and container
labelling

Required

Not
Required

Required

Required

Required

Dispatch and receipt

Required

Required

Required

Required

Required

Transportation and products in
transit

Required

Not
Required

Not
Required

Required

Required

Documentation

Required

Required

Required

Required

Required

Repackaging and relabelling

Required

Required

Required

Not
Required

Required

Complaints

Required

Required

Required

Required

Required

Recalls

Required

Required

Required

Required

Required

Returned products

Required

Not
Required

Required

Required

Required

Counterfeit pharmaceutical products

Required

Required

Required

Required

Required

Importation

Required

Not
Required

Required

Required

Required

Contract activities

Required

Required

Required

Required

Required
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Self-inspection

Required

Not
Required

Required

Required

Required

Donated Pharmaceutical products

Not
Required

Required

Not
Required

Not
Required

Not
Required

Qualification of suppliers and
customers

Not
Required

Required

Not
Required

Required

Required

Measurement, Analysis and
Improvement

Not
Required

Not
Required

Not
Required

Not
Required

Not
Required

Operations

Not
Required

Not
Required

Not
Required

Not
Required

Required

Validation and Change Control

Not
Required

Not
Required

Not
Required

Not
Required

Not
Required

Specific provisions for Brokers

Not
Required

Not
Required

Not
Required

Not
Required

Required

Quality System

Not
Required

Not
Required

Not
Required

Not
Required

Required

Findings from this study have identified the need for
a specific and separate Assessment Tool for the
Observed Regulatory Agency in West Africa, for new
and routine GDP inspections of all premises involved
in any aspect of distribution, including manufacturing
premises that also distribute their own products. This
will ensure global best practices in GDP. The
findings from the Gap Analysis guided the
development of the proposes GDP Assessment
Tool.

Table 3 shows the major titles in the proposed GDP
Assessment Tool. A copy of the proposed new and
routine GDP assessment tool for assurance of good
distribution practice is attached as Annex 1.

Figure 3
Major Titles in the Proposed GDP Assessment Tool

S/No.

Major Sections in the Proposed GDP Assessment Tool

1

Particulars of facility, including name, address and contact of the company/facility

2

Personnel

3

Distribution authorization

4

Organizational structure

5

Location, design and construction of building facilities

6

Layout of premises and facilities

7

7

Commodity storage conditions

8

Documentation and record keeping

9

Complaints, returns, damaged, expired, suspected

10

Vehicles and equipment

11

Falsified medicinal products and product recalls

12

Poison control

13

Supplier and customer qualification

14

Reference books

15

Quality control

16

Names and signatures of inspectors

DISCUSSION
The proliferation of counterfeit and unwholesome
processed medicines and increasing incidence of
uncoordinated access to medicines, abuse and
misuse of medicines, irrational dispensing and use of
medicines are in part, a result of uncoordinated
channels of procurement and supply chain
management of medicines. The World Health
Organization (2010) and European Union Guidelines
(2013) have defined Good Distribution Practice as
an essential tool to secure the distribution system
from counterfeits, unapproved, illegally imported,
stolen, substandard, and/or misbranded
pharmaceutical products. The lack of a separate
GDP Assessment Tool for the Observed Regulatory
Agency in West Africa has adversely affected
regulatory functions, as majority of the inspectors
ignore some of the GDP components of the GMP
inspection form, as shown on Figure 2. Findings
from review of the proficiency of the activities of the
inspectors with respect to quality of the Good
Manufacturing Practices inspection report shows a
disconnect among pharmaceutical inspectors in
various regions of the country. The assessment,
interpretation and reporting of indices, observations
and conclusions of the GDP parameters were
subjectively made. It is likely that if there was a
separate GDP assessment tool and the inspection

was being carried out on a separate day,
independent of GMP inspections, consistent quality
inspection outcomes would have been available.
Among the core GDP parameters, none of the
inspection reports recorded list of products, name
and address of the pharmaceutical premises.
Parameters with lowest figures (frequency of
reporting) included key personnel (6%),
transportation and handling of raw materials (9%),
finished product quarantine store (17%), finished
product approved store (23%), packaging materials
store (17%) and distributors accredited guidelines
(29%) (Figure 3). In addition, these parameters
addressed the activities in the production areas and
do not address the major distribution activities and
processes beyond production. Thus, it is unlikely that
a robust GDP inspection is carried out in the
absence of a separate GDP assessment. There is
therefore need for a separate and robust GDP
Assessment Tool outside the GMP inspection Tool,
and to carry out GDP inspections separate from
traditional GMP inspections.
Many scholars have studied the drug distribution
practices and systems in West Africa. A study
conducted, National Drug Distribution in Nigeria;
Implications for the Goals of National Drug Policy,
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reported that the present drug distribution system in
Nigeria is uncoordinated, porous and a serious

threat to the National Drug Policy (NDP). Open drug
markets abound with quacks operating freely across

the value chain. Out-of-Stock syndrome is very
common in government hospitals. Drug
management information systems are comatose and
that the situation continues to undermine the
objectives of the NDP and takes its toll on the
National Health Policy (Ogbonna, B. O., 2015).
Nigeria introduced the Guidelines on National Drug
Distribution in 2012 with the goal of establishing a
well ordered drug distribution system in Nigeria
aimed at ensuring efficient and effective drug supply
management in the public and private sectors, and
ensure that all drugs in the national drug distribution
system are safe, efficacious, effective, affordable,
and of good quality (FMOH, 2012).

pursued in isolation and will require fundamental
changes in the structure of healthcare financing and
regulation. Additionally, supply chain reform cannot
be achieved or sustained without strong leadership
in the health sector and a strong and skilled supply
chain workforce (Prashant Y., 2015). Recent supply
chain reform in Zambia has shown that careful
analysis, political will, and strong managerial talent
can lead to better performing supply chain and
reduce disease morbidity and mortality (World Bank,
2011).

A standard distribution system is expected to have
structures that ensure security while maintaining a
streamlined structure, good condition of drugs,
constant supply, and provides reliable information for
forecasting, pharmacovigilance, monitoring and
recalls. The effectiveness and efficiency of drug
distribution lies on good system design, efficiency,
effective management, and standard logistic
management information system (LMIS) (Benneth,
2008; FMOH, 2012; Donner G.E. et al., 1992). In
addition, the World Health Organization noted that
weak points in the distribution processes of
pharmaceutical products provide an avenue for
counterfeit as well as illegally imported, stolen and
substandard medicines to enter the supply chain.
The methods by which such products enter the
supply chain have become increasingly complex and
have resulted in the development of thriving
secondary and grey markets throughout the world.
The involvement of unauthorized entities in the
distribution and sale of pharmaceutical products is a
particular concern. Therefore, the implementation of
Good Distribution Practice is of paramount
importance to patient safety as the global supply
chain is becoming complex and fragmented. It is
essential to protect the pharmaceutical supply chain
against the penetration of counterfeit and
unwholesome processed medicines through efficient
regulation and control. Pharmaceutical supply chains
are highly vulnerable to corruption from product
registration and procurement to last mile distribution
(Vian T., 2008; Bateman C., 2013; Roberts M. J., et
al., 2011). A study conducted on health supply
chains in developing countries reported that
promoting good governance and creating greater
transparency of product flow information in the
health sector supply chain is an important prerequisite for many of the technical solutions and that
in some cases, supply chain reform cannot be

Globally, deliberate training of pharmaceutical
inspectors has been a strategy to ensure quality
regulation for the improvement of patients’ health.
Pharmakon is the World Health Organization
Collaborating Centre for Drug Policy and Pharmacy
Practice Development, which provides training for
pharmaceutical inspectors in the European Region.
In order to ensure the effectiveness of the learning
process, trainers at Pharmakon are using a
methodology with the optimal combination of
theoretical and presentation materials, role play,
individual and group tasks for the trainees and
hands-on exercises. Also, it is an established
practice that each training module is followed by
critical individual appraisal for each trainee (WHO
Russian Federation, 2014).
Trainers at Pharmakon have extensive practical
experience of work with pharmaceutical inspectors
from European regulatory authorities. The detailed
analysis of real-life situations in the preparation and
execution of the inspections of pharmaceutical
manufacturers, the expertise in the classification of
observations, the ability of keeping the inspection
direction and the adherence to the ethical and
professional principles facilitated the learning
process. According to the WHO, the use of the
unified approach in training will better support close
collaborations between inspectors, alongside the
harmonization of the medicines regulatory standards
and approaches for the inspection of pharmaceutical
manufacturers in the Region (WHO Russian
Federation, 2014).
In addition, annual Pharmaceutical Inspection Cooperation/Scheme (PIC/S) Training Seminars are
open to inspectors from PIC/S Participating
Authorities and other interested Medicine Regulatory
Authorities. Each seminar focuses on a particular
aspect of GMP and/or GDP with the aim of providing
training and harmonization in the field
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covered. PIC/S seminars last for about 2-5 days, not
profit-oriented and are attended on average by more
than 100 Inspectors from all over the world. They are
organized by Regulatory Authorities for Regulatory
Authorities in line with the PIC/S Aide-Memoire on
Organization of Seminars (PIC/S, 2020).
New Inspector Training Courses are to be designed
for new pharmacists who are expected to be
involved in inspection of pharmaceutical premises
whether they have previously observed or
participated in GDP inspections or not, and who
would like to develop inspection skills necessary to
assess compliance of distributors against the GDP
Guide (PIC/S, 2020).

CONCLUSION
Based on the study findings, an Assessment Tool,
specifically for Good Distribution Practices was
developed and proposed to the Regulatory Agency
in order to address existing gaps in inspection. It is
expected to be applicable to manufacturers who also
distribute their own products, distributors,
coordinated wholesale centres, wholesalers and
retailers.

RECOMMENDATIONS FOR NEXT STEPS
•

•
•
•

Adopt the proposed GDP Assessment Tool, train
inspectors on it and develop its own guidelines
for the regulation of Good Distribution Practice in
the country, using the WHO guideline as a
template. The guidelines are to assist in
ensuring the quality and identity of
pharmaceutical products during all aspects of
the distribution process (WHO, 2010);
Carry out GDP assessments independent of
GMP assessments, in order to achieve an
impactful and robust regulation;
Include distribution supply chain in GDP
assessments;
Train all pharmaceutical inspectors on uniform
assessment and interpretation of indices and
reporting of observations and conclusions.
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Annex 1
PROPOSED NEW AND ROUTINE INSPECTION/ASSESSMENT TOOL FOR ASSURANCE OF GOOD
DISTRIBUTION PRACTICE
I.

PARTICULARS OF FACILITY

Name of the
Company/Facility
⬜ Retail
⬜ Wholesale
Type of facility

⬜ Coordinated Wholesale Centre
⬜ Distribution
⬜ Mega Drug Distribution

Physical and Contact Address
Local Government Area
State
Information on Inspection
Date of location inspection
Date of current Inspection
Purpose of Current Inspection

2. PERSONNEL
Superintendent Pharmacist
Name:

12

Phone Number:
Email:
Full Registration Number
Annual License Number with
date
Names and telephone numbers of other key personnel
Inventory Manager
Store Officer
Quality Control Officer
Procurement Officer
II.
3. DISTRIBUTION AUTHORIZATION
QUESTION
S/N

(Please tick as
appropriate)
Is the annual license
of the superintendent
pharmacist available?

Are the annual
licenses of the other
pharmacists
available?

YES

NO

COMMENTS

GUIDELINES

Check current license of the Superintendent
Pharmacist
Receipt of payment for the current year is
acceptable if license for previous year is
sighted
Check current licenses of the other
Pharmacists
Receipt of payment for the current year is
acceptable if license for previous year is
sighted
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If a previously
registered premises,
is the certificate of
registration of the
premises available?

Check copy of the certificate of registration of
the premises issued by PCN
Receipt of payment for the current year is
acceptable if license for previous year is
sighted

Is the certificate of
CAC registration of
the company
available?

Check the certificate of registration of the
company issued by CAC

4. ORGANIZATIONAL STRUCTURE
QUESTION
S/N

(Please tick as
appropriate)

YES

NO

COMMENTS

GUIDELINES

Is the organizational
structure defined with
responsibilities and
relationships of all
personnel, clearly
indicated?

Check organization chart (organogram)

Are responsibilities and
roles of employees
working in key
positions defined?

Check Job Descriptions of key personnel

Are the personnel
adequately and
appropriately trained in
courses relevant to
their tasks?

Check evidence of in-house and external
trainings undertaken by the personnel, including
trainings on supply chain efficiency, inventory
management, cost optimization, loss
minimization, reverse logistics, standard storage
practices, meeting patients’ needs
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Is the practical
effectiveness of
training periodically
assessed and
documented?

Check training curricula, evaluation tools,
certificates of participation, if applicable

5. LOCATION, DESIGN AND CONSTRUCTION OF BUILDING FACILITIES

S/N

QUESTION
(Please tick as appropriate)
Does the structure meet the
required dimensions?

YES

NO

COMMENTS

GUIDELINES

•

Minimum dimensions:

•

Retail: 30m2

•

Wholesale: 50m2

•

Mega Distribution
Centres:1000m2

•

Coordinated Wholesale
Centres: Not be less than 200
Outlets, each having a
minimum size of 70m2 in size

Is the premises made of concrete
walls?

A Pharmaceutical premise shall be
made of concrete walls and not in
the form of kiosk or bull-doff

Is the premises located close to an
existing
Wholesale/Distribution/Retail?

Check the required distance and
confirm if it’s up to 200m for
retailer and Wholesaler and 2 km
for CWC

Is the premises located close to a
Refuse Dump site?

Check the required distance and
confirm if it’s up to 200m from a
refuse dump site

Is the premises located close to an
Erosion Control site?

Check the required distance and
confirm if it’s up to 200m from an
Erosion Control Site
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Is the premises located close to a
cement factory?

Check the required distance and
confirm if it’s up to 200m

Is the premises located near a
clustered area?

No premises shall be located in an
environment where commercial
activities and enterprises are
growing very close together?

Is the premises located close to a
petrol station?

Check the required distance and
confirm if it’s up to 200m from a
petrol station

6. LAYOUT OF PREMISES AND FACILITIES
S/N

QUESTION
(Please tick as appropriate)

YES

NO

COMMENTS

GUIDELINES

Are measures in place to
prevent unauthorized access to
sensitive sections?

Check SOP, locks and labels on entrances
of sensitive sections such as storage of
prescription and scheduled medicines

Are receiving and dispatch bays
in place and appropriate?

Check that receiving and dispatch bays
are constructed to protect products from
prevailing weather conditions

Are segregated areas
designated for the storage of
any product that is not to be
sold?

Check the availability of segregated areas
for products suspected of falsification,
returned products, rejected products,
products awaiting disposal and recalled
products

Is there adequate separation
between the receipt/dispatch
areas and storage areas?

Check for well-furnished
reception/invoicing area

Are the rest, wash and
refreshment rooms adequately
separated from the storage
areas?

Check for availability of rest, wash and
refreshment rooms in designated areas
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Is the floor tiled, well maintained
and clean?

Inspect the floor for tiles, cleanliness and
check evidence of routine cleaning

Are the walls clean and wellpainted?

Inspect the walls for cleanliness and
aesthetics

Is the ceiling in good condition?

Check that the ceiling is well constructed
with no signs of leakage

Is there a superintendent
pharmacist’s office?

Check designated area as Pharmacist’s
office with adequate furniture and facilities

Is there an administration office?

Check designated area as administration
office with adequate furniture and facilities

Is there an office for other staff,
such as store officer etc.?

Check designated area as office for other
staff with adequate furniture and facilities

Is there a packing area and
store, clearly partitioned and out
of view of the reception area?

Check that the packaging area and store
meet the standard prescribed minimum of
15m2

Are OTC Drugs separated from
Ethical Drugs?

Check to confirm OTC drugs are
separated from Ethical drugs

Are there job aids available for
different logistics tasks?

Check job aids for different logistics tasks
(filling in bin card, uploading data into
software, flowcharts etc.) and evidence of
compliance.

Is there an alternative source of
electricity supply?

Check for other functional sources for
maintenance of uninterrupted supply of
electricity

SAFETY AND HYGIENE

Are there smoke detector(s)/fire
alarms and fire extinguisher/
sand bucket in the premises?

Check for smoke detector(s)/fire alarms
and fire extinguisher/s and bucket
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Is there a ‘’No Smoking” sign?

Check for displayed ”No Smoking” and
Flammable materials signs

Is there a First Aid kit?

Check for First Aid kit and inspect content
for adequacy and potency

Are cleaning instructions and
records, sanitation procedure in
place?

Check SOP for sanitation of storage area
and premises and Check evidence of
routine cleaning

Are the inside of the structure
and the surroundings clean?

The inside of the structure must not be
dirty, disorderly or in a state of disrepair

Are procedures relating to
personnel hygiene and clothing
established and observed

Check SOPs as appropriate

Are facilities designed and
equipped so as to afford
protection against the entry of
insects, rodents or other
animals?

Check for signs of pest infestation i.e. pest
droppings, evidence of nesting (shredded
paper, grass clippings etc.)

Is there a preventive pest control
programme in place?

Check for rodent control measures like an
agreement/contract with a fumigation
company – certificates and Insectocutors

Is there a certificate of recent
fumigation (not more than 6
months) available?

Check displayed certificate of recent
fumigation

Is storage of food, drinks, or
medications for personal use
prohibited in storage areas?

Check appropriate SOPs and presence of
foods, drinks and medications for personal
use in storage areas

7. COMMODITY STORAGE CONDITIONS

S/N

QUESTION
(Please tick as appropriate)

YES

NO

COMMENTS

GUIDELINES
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Are the storage areas
temperature mapped?

Check records of temperature mapping

Is the temperature monitoring
equipment located according to
the results of the mapping
exercise?

Check locations of thermometers to
ensure appropriate placement

Are controls and devices
adequate to maintain storage
areas within defined
temperature, humidity or light
parameters, available?

Check availability of functional
temperature and humidity monitoring
devices and charts

Is the equipment used to
control or monitor the
environment calibrated
appropriate methodology?

Check SOP for calibration and evidence
of calibration

Are appropriate alarm systems
in place to provide alerts when
there are deviations from predefined storage conditions?

Check availability of calibrated alarm
systems

Are the alarm levels
appropriately set and regularly
tested?

Check availability of calibrated alarm
systems

Are the shelves and pallets
clean and in good condition?

Inspect the shelves and pallets for
cleanliness (dust free, no pest
droppings) and good condition
(maintains its integrity)

Are boxes kept on pallets or
shelves or cupboards?

Ensure boxes are not kept on the floor
or against the walls

Are shelves well arranged?

Check shelves to confirm drugs are
arranged in a logical manner

Are medicinal products stored
separately from other
products?

Check the shelves and pallets for nonmedicinal product among medicinal
products
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Are the commodities arranged
in an orderly manner and not
stored directly on the floor?

Check that commodities are kept on
shelves and pallets; not on the floor or
against the walls

Are medicinal products
protected from harmful effects
of light, temperature, moisture
or other external factors, in a
dry, well-lit, and well-ventilated
storeroom, out of direct
sunlight?

Check store for functioning bulbs,
minimum of two windows situated
alternately and protection from direct
sunlight

Are cartons arranged at least
one foot away from the wall
with arrows pointing up and
identification labels,
manufacturing and expiry dates
clearly visible?

Check that cartons are arranged with
arrows pointing up (˄), and identification
labels, (manufacturing and expiry dates)
clearly visible

Is stock rotation according to
the expiry dates of batches
("first expired first out"–FEFObasis)?

Check that commodities are supplied
based on FEFO (first expiry first out)
policy

Are expired goods stored
separately?

Check record of expired commodities
and evidence of handling disposal

Ask the staff to explain the
process of disposal & check
related documents

Check that segregation is provided for
the storage of rejected, expired, recalled
or returned products and suspected
falsified medicinal products

Are damaged goods stored
separately?

Ask the staff to explain the process of
disposal & check related documents.
Check record of damaged commodities
in separate storage and evidence of
handling their disposal.

Are flammable products stored
separately and distant from
other products?

Check for segregation of flammable
products away from other products

Are inventory irregularities
investigated and documented?

Check evidence of stock taking and
reconciliation
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Is cold storage equipment
available and used in the
facility? If yes, which ones?

Compulsory for facilities that deal in
thermo labile products

Cold Room

Check adequacy and functionality of
equipment

Refrigerator/Freezer/Medical
Refrigerator

Check adequacy and functionality of
equipment

Cold boxes/vaccine carriers

Check adequacy and functionality of
equipment

Are commodities stored under
appropriate storage conditions
as indicated on the labels?

Check commodities are stored as
indicated on the label

Are updated temperature logs
available in the store?

Check that temperature logs are
regularly updated

Are there functional
refrigerators and air
conditioners?

Check availability and functionality of
refrigerators and air conditioners for
facilities that store thermo-labile
products

Are vaccines potency
monitored using VVM (vaccine
vial monitor)?

Check evidence of VVM check for all
vaccines. Specify type of changes
observed

Are random samples of
commodities subjected to
visual inspection?

Check schedule of random sampling of
visual inspection of commodities

8. DOCUMENTATION AND RECORD KEEPING
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S/N

QUESTION
(Please tick as appropriate)

YES

NO

COMMENTS

GUIDELINES

Are there personnel in charge
of documentation and record
keeping?

Check job description of staff reflects
the responsibility.

Are there SOPs for
documentation and record
keeping?

Check Sops or documentation and
record keeping

Are documentation and record
keeping done in line with
SOPs?

Check that documentation is done in
Bin Cards and/ or inventory control
software

Are SOPs approved?

Check that SOPs are signed and
dated by appropriate authorised
persons

Are SOPs reviewed regularly

Check regular review and up-dating of
SOPs

Is there a stock/drug register
or LMIS for inventory
management, besides the
stock card?

Check stock card and available
alternative inventory management
system. (LMIS is Logistics
Management Information System)

Are documents are retained
for a period stated in national
legislation but at least 5 years
at a separate, secure
location?

Check SOP for retention of document

Is data entered into
computerized system and
amended only by persons
authorized to do so?

Check SOP for use and handling of
computerized data

Is computerized data
protected by backing up at
regular intervals

Ask staff to demonstrate data backing
up process

22

Is data secured by physical or
electronic means against
willful or accidental damage?

Check data security in the event of
accidental or willful damage

9. COMPLAINTS, RETURNS, DAMAGED, EXPIRED, SUSPECTED FALSIFIED MEDICINAL
PRODUCTS AND PRODUCT RECALLS
S/N

QUESTION
(Please tick as appropriate)

YES

NO

COMMENTS

GUIDELINES

Complaints
Is there a written procedure in
place for the handling of
complaints?

Check SOP for handling of
complaints

Are distinctions made between
complaints about the quality of a
medicinal product and those
relating to distribution?

Check SOP for handling of
complaints

Returned Medicinal Products

Are written procedures in place for
the handling and acceptance of
returned medicinal products?

Check for availability of SOPs for
handling returned medicines

Suspected falsified medicinal
products
Are the staff aware of the risks of
falsified medicinal products
entering the supply chain?

Check evidence of relevant
training

Is there SOP for immediate action
if medicines are identified or
suspected to be falsified or
substandard?

Check procedure for informing
competent authorities and
marketing authorisation holders
of suspected falsified or
substandard medicinal products
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Expired Medicinal Products

Are there written procedures for
handling of expired medicines?

Check procedure for handling
expired medicines to confirm that
it is in line with standard
procedures

Are there any expired medicines
on the shelf?

Check samples of medicines
from different shelves, randomly
picked

Medicinal Products Recalls

Is there a written procedure for the
management of recalls?

Check SOP for Product Recall

Are the management of recalls and
its effectiveness periodically tested
and evaluated?

Check evidence of mock recalls

Is the product movement/recall
chart available?

Check Product Recall charts and
if the recall operations are
recorded at the time they are
carried out

Are distribution records readily
available to the person(s)
responsible for the recall?

Check SOPs and materials
available for recalls

Is the progress of call process
recorded and a final report issued?

Reconcile between the delivered
and recovered quantities of the
medicinal products

10. VEHICLES AND EQUIPMENT
S/N

QUESTION
(Please tick as appropriate)

I I

YES

I

NO

I

COMMENTS GUIDELINES

I
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Are vehicles and equipment suitably and
appropriately equipped?

Check that there is no
exposure of the products to
conditions that could affect their
quality and packaging integrity,
and contamination of any kind

Are procedures in place for the operation
and maintenance of all vehicles and
equipment?

Check relevant SOPs including
those of cleaning and safety
precautions

Are required storage conditions maintained
during transportation?

Check conditions of the vehicle
and compare with
specifications on product label

Is transportation performed in safe,
dedicated, and secure containers and
vehicles?

Check physical conditions of
the vehicle

Are validated temperature-control systems
used to ensure correct transport
conditions?

Check for thermal packaging,
temperature-controlled
containers, and refrigerated
vehicles, if applicable

If refrigerated vehicles are used, is
temperature mapping performed under
representative conditions?

Check that the representative
conditions include seasonal
variations

Are the equipment used for monitoring
conditions calibrated at regular intervals?

Check that temperature and
humidity monitoring equipment
within vehicles and containers
are calibrated at least once a
year

Is there written procedures for delivery of
sensitive products and control of seasonal
temperature variations?

Check relevant SOPs

If cool-packs are used in insulated boxes,
are they located such that the product does
not come in direct contact with the coolpack?

Check SOP
Do physical assessment
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Are the staff trained on the procedures for
assembly of the insulated boxes

Check that training includes
seasonal configurations and
the reuse of cool-packs

Are there written procedures for
management of unexpected occurrences?

Check SOP for management of
unexpected occurrences such
as vehicle breakdown or nondelivery

Is a procedure in place for investigating
and handling temperature excursions?

Check for automated
notification software when
temperature is out of
specification and SOP for
handling it

Are there procedures for using nondedicated vehicles and equipment?

Check that SOP ensures that
the quality of the medicinal
product will not be
compromised

Are delivery drivers (including contract
drivers) trained in the relevant areas of
GDP?

Check evidence of training

Are deliveries made directly to the address
stated on the delivery note?

Check vehicle movement logs
and delivery notes

When using transportation hubs, has the
maximum time limit for storage in these
locations been defined?

Check SOP for using
transportation hubs

When using transportation hubs, are the
premises audited and approved prior to
deployment?

Check for evidence of approval

Are there specifications and parameters for
qualifying transport hubs?

Check SOP and guidelines for
qualification of transport hubs

Is the realist of Hubs qualified and used by
the transportation company?

Check availability of list of hubs
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Are there written procedures when
transportation is not directly operated by
the premises?

Check for SOPs for contracting
and outsourcing transport
activities, with clarity of duties
and responsibilities of each
party

Are the contract and SOP for outsourcing
in line with standard specifications for
transport of the premises?

Check for specifications in the
contract and SOP

11. POISON CONTROL

S/N

QUESTION
(Please tick as appropriate)

YES

NO

COMMENTS

GUIDELINES

Is there a poison cabinet with
safety lock and key?

Check poison cabinet

Are there evidences of
prescriptions prior to dispensing
of poisons?

Check for evidence of prescriptions
for poisons dispensed and
maintenance of prescription file

Is there a Poison Disposal
Register with proper entries?

Check Poison Register filled with
name and signature of patient,
details of product e.g. name,
strength, pack size, quantity, batch
number, NAFDAC number, expiry
dates etc. and name and signature
of dispensing pharmacist

12. SUPPLIER AND CUSTOMER QUALIFICATION
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S/N

QUESTION
(Please tick as appropriate)

YES NO COMMENTS

GUIDELINES

Are all supplies of medicinal
products obtained only from
persons/organisations with
distribution or manufacturing
authorisation, for the product in
question?

Check for evidence of authorization
from the appropriate Regulatory
Agency (PCN)

Is there verification of compliance
to GDP guidelines by the supplier
when medicinal products are
obtained from another distributor?

Check relevant SOPs and
documentation

Is the supply chain (including
procurement) of medicinal products
controlled by written procedures?

Check for SOPs for procurement of
medicinal products

Is qualification and approval of
suppliers controlled by a standard
operating procedure?

Check for the SOP

Are the results of qualification and
approval of suppliers documented?

Check documentation for supplier
qualification

Are the results of qualification and
approval of suppliers periodically
rechecked?

Check evidence of periodic recheck

Qualification of Customers
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Are medicinal products only
supplied to persons/organisations in
possession of a distribution
authorization or who are authorized
or entitled to supply medicinal
products to the public?

Request copies of customer's
authorisations
Request evidence of qualifications or
entitlement according to national
legislation

Is the qualification of customers
appropriately documented?

Check availability of document

13. REFERENCE BOOKS

S/N

QUESTION
(Please tick as appropriate)

YES

NO

COMMENTS

GUIDELINES

Martindale’s The Extra
Pharmacopoeia

Check for availability of the hard copy
and/or soft copy of the document

BNF and/or Emdex

Check for availability of the document
(hard copy)

National Formulary and
Essential Medicines List

Check for availability of the document
(hard copy)

A compilation of Pharmacy,
drugs and related laws, rules in
Nigeria, 1935, 2000

Check for availability of the document
(hard copy)

Merck Manual

Check for availability of the document
(hard copy)

Four-part compendium of
minimum standards for the
assurance of pharmaceutical
care in Nigeria

Check for availability of the document
(hard copy)
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British Pharmacopoeia

I

I

I

Check for availability of the document
(soft and/or hard copy)

I I

QUESTION
S/N

(Please tick as
appropriate)

YES

NO

COMMENTS

GUIDELINES

Are the available
medicines registered
with NAFDAC?

Check Inventory for NAFDAC number of
medicines

Are there supplies
from illegal
premises?

Check list of approved suppliers

Is there SOP for
quality of supplies

Check evidence of SOP for selection of
supplies

Check ten line items from different shelves
randomly for compliance

Check invoices for supplies

14. QUALITY CONTROL
QUESTION
S/N

(Please tick as
appropriate)

YES

NO

COMMENTS

Is there a quality
control/mini
assurance lab?

GUIDELINES

Check for functionality and documentation
-

CWC

-

Distributor

-

MDD

15. NAMES AND SIGNATURES OF INSPECTORS
1. …………………………………………………………………………………………………………………………
2. …………………………………………………………………………………………………………………………
3. …………………………………………………………………………………………………………………………
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4. …………………………………………………………………………………………………………………………
5. …………………………………………………………………………………………………………………………
6. …………………………………………………………………………………………………………………………
7. …………………………………………………………………………………………………………………………
8. …………………………………………………………………………………………………………………………
9. …………………………………………………………………………………………………………………………

